Alternatively, the combination of WP 631 and sitagliptin (a dipeptidyl peptidase-4 inhibitor used for the treatment of type 2 diabetes) did not enhance the cytotoxic effects of WP 631 on HepG2 cells. Here, DPP4 is linked to type 2 diabetes mellitus.